Scientists Develop Artificial Intelligence for Mesothelioma Assessment

Scientists in Scotland have developed a prototype imaging system using artificial intelligence that has proven effective with malignant mesothelioma, potentially revolutionizing the way patients will be treated in the future. The pilot program could spark much-needed advances in diagnostics and therapeutics. “Mesothelioma is such a complex, incredibly difficult disease,” Dr. Kevin Blythe, professor of respiratory medicine at University of Glasgow and respiratory physician at Queen Elizabeth University Hospital, told The Mesothelioma Center at Asbestos.com. “This could be a very important step toward helping patients in the future.” The University of Glasgow and Canon Medical Research Europe worked together in developing the novel technology built around artificial intelligence, or AI. The computer software can detect and measure cancer cells more effectively than traditional imaging. It could be used to more accurately – and quickly – assess a mesothelioma patient’s immediate response to drug treatments such as chemotherapy and immunotherapy. AI Could Provide More Personalized Treatment The project, which was launched in 2018, was focused intentionally on mesothelioma, a rare but aggressive malignancy, and one of the most difficult-to-measure with traditional CT scans. Scotland, with a long history of shipbuilding and the use of asbestos in construction, has one of the world’s highest incidence rates of meso...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

AbstractCytokeratins (CKs) 5 and 6 are functionally unrelated but  often analyzed together using bispecific antibodies in diagnostic immunohistochemistry. To better understand the diagnostic utility of CK5 or CK6 alone, tissue microarrays with >  15,000 samples from 120 different tumor types as well as 608 samples of 76 different normal tissues were analyzed by immunohistochemistry. In normal tissues, both CKs occurred in the squamous epithelium; CK5 dominated in basal and CK6 in suprabasal layers. CK5 (not CK6) stained basal cells in v arious other organs. Within tumors, both CK5 ...
Source: Virchows Archiv - Category: Pathology Source Type: research
To the Editor:
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
o Comba Alessandro Marinaccio Asbestos is one of the major worldwide occupational carcinogens. The global burden of asbestos-related diseases (ARDs) was estimated around 231,000 cases/year. Italy was one of the main European asbestos producers until the 1992 ban. The WHO recommended national programs, including epidemiological surveillance, to eliminate ARDs. The present paper shows the estimate of the burden of mortality from ARDs in Italy, established for the first time. National standardized rates of mortality from mesothelioma and asbestosis and their temporal trends, based on the National Institute of Statistics...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Article Source Type: research
This study suggests quinacrine may have repurposing potential for a large subset of mesothelioma patients.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
The publisher regrets that the authorship list was omitted from the header of this article. The correct authorship list can be found above
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Erratum Source Type: research
ConclusionsTreatment of advanced-stage rare tumours with ICI therapy was found to be associated with significant activity in some orphan diseases (e.g., Merkel cell carcinoma) and hepatocellular carcinoma. Several ongoing prospective clinical trials will expand the knowledge on the safety and efficacy of ICI therapy in patients with these rare cancers.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
DISCUSSION: In our real-world analysis of patients with aMPM treated at an academic referral centre, systemic treatment was given to the majority of patients and benefit was seen even in the elderly and poor PS patients frequently underrepresented in clinical trials. Trial participation was potentially facilitated by the formation of a dedicated multidisciplinary MPM clinic.PMID:34531139 | DOI:10.1016/j.cllc.2021.08.003
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Nutr Cancer. 2021 Sep 17:1-10. doi: 10.1080/01635581.2021.1980592. Online ahead of print.ABSTRACTMesothelioma is a highly lethal cancer developing in the lung, heart, and abdominal membranes. Zingerone, a capsaicin-like bioactive compound, has been shown to have anticancer properties. Transient Receptor Potential Vanilloid 1 (TRPV1) is an ion channel involving in the cytotoxicity of capsaicin. In the present study, we aimed at determining the cytotoxicity of zingerone on a mesothelioma cell line and to evaluate the role of TRPV1 in this effect. For this purpose, H2452 was used as the mesothelioma cell line and MTS was perf...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Source Type: research
Imagine a world in which physicians can confidently cure cancer. Two Bay Area life sciences companies are working together to make this vision a reality. Atara Biotherapeutics Inc., founded in 2012, is developing a pipeline of cell therapies to treat various types of cancer and autoimmune diseases. Bayer is licensing Atara’s cutting-edge cell therapies that t arget certain types of aggressive tumors including mesothelioma, pancreatic, ovarian and non-small-cell lung cancer. “With cancer therapies,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news
The 16th Annual International Asbestos Awareness and Prevention Conference takes place Sept. 17-18, featuring 40 speakers from seven countries plus the first-ever Art, Advocacy and Shared Stories film festival. This virtual event is open to all free of charge, requiring only an online registration. It is designed to educate the public about the dangers of asbestos, intensify efforts to ban asbestos, and aid in research to improve treatment for asbestos diseases, including mesothelioma cancer. Sponsoring the event is the Asbestos Disease Awareness Organization, an independent nonprofit regarded as the world’s le...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Computers | CT Scan | Environmental Health | Hospitals | Immunotherapy | Mesothelioma | Palliative | PET Scan | Research | Respiratory Medicine | Scotland Health